OSAKA, April 17,2023 – FUJIFILM Wako Pure Chemical Corporation (President: Koichi Yoshida) announces that it has established the Pharmaceutical Materials Division in April this year to further expand its pharmaceutical materials business. The Pharmaceutical Materials Division is an organization that designs and promotes overall strategies for the pharmaceutical materials business, including raw materials for pharmaceutical manufacturing, culture media and additives necessary for cell culture, and process development and contract manufacturing of active pharmaceutical ingredients. In conjunction with the establishment of the Pharmaceutical Materials Division, the company has commenced a new service that customizes the volume and form of raw materials for pharmaceutical manufacturing in response to customer requests.
FUJIFILM Wako Pure Chemical is strongly promoting the business of raw materials for pharmaceutical manufacturing as well as process development and contract manufacturing of culture media and additives required for cell culture in R&D and manufacturing of biopharmaceuticals and regenerative medicine products, and process development and contract manufacturing of small molecule active pharmaceutical ingredients. The company has been enhancing its line-up of raw materials for pharmaceutical manufacturing and strengthening its sales, as seen in the 2017 introduction of the CertiPro Series manufactured under GMP and CertiPro-L Series manufactured under ISO9001.
To further expand its pharmaceutical materials business, FUJIFILM Wako Pure Chemical has established the Pharmaceutical Materials Division. The new division designs and promotes overall strategies for the pharmaceutical materials business, including raw materials for pharmaceutical manufacturing, culture media and additives, and process development and contract manufacturing of active pharmaceutical ingredients for small molecule drugs.
Focusing on the pharmaceutical raw materials business, the company will increase its line-up especially for the growing application of biopharmaceuticals and expand its CertiPro and CertiPro-L Series. Furthermore, the company has launched new services to meet the diverse needs of customers. The services include a service to change the volume and packaging materials to meet customers' requirements, and a service to convert powders into solutions by utilizing the technologies and know-how the company has cultivated in the reagent manufacturing.
In addition, the company will strengthen information dissemination through the dedicated website for raw materials for pharmaceutical manufacturing (https://labchem-wako.fujifilm.com/us/pharmaceutical-raw-materials/index.html) opened in March 2023.
By further enhancing its pharmaceutical material products and services, FUJIFILM Wako Pure Chemical will strongly support its customers’ R&D and manufacturing of new drugs.
Under the mission of “With commitment to the future of science, our company is dedicated to create the source of happiness for all people,” FUJIFILM Wako Pure Chemical will continue to develop and provide highly functional and high-quality products that meet the needs of society and customers, and contribute to the development of industry and academic research in a wide range of fields, including pharmaceuticals.
| For inquiries on information in this press release, contact: | |
| Media contact: | FUJIFILM Wako Pure Chemical Corporation https://www.fujifilm.co.jp/form/ffwk/en/general/input.php?id=FFWKGeneralEn |
| Product / service inquiry: | FUJIFILM Wako Pure Chemical Corporation Sales Promotion Section Email: ffwk-labchem-tec@fujifilm.com |